- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option - SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a ...

Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial ...

Crinetics Pharmaceuticals announced that it will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, highlighting the investigational treatment ...

A Prescription Drug User Fee Act target date of September 25, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for paltusotine ...

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...

October 13, 2010 (Liege, Belgium) — In patients with treatment-resistant, active acromegaly, normalizing insulin-like growth factor 1 (IGF-1) levels leads to a marked reduction in cardiovascular risk, ...

Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly are more likely to have hypertension, diabetes and other comorbidities than healthy ...

A personalized treatment protocol was more effective for management of acromegaly -- also known as gigantism -- than the usual trial-and-error approach, the ...

Please provide your email address to receive an email when new articles are posted on . An AI model correctly identified 22 of 31 adults as having acromegaly strictly based on voice recordings. The ...

The journal Pituitary has highlighted research led by Manel Puig, head of the Endocrine, Thyroid and Obesity Research Group at the Germans Trias i Pujol Research Institute (IGTP), which explores the ...

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the ...